Zammit Stanley, Allebeck Peter, Andreasson Sven, Lundberg Ingvar, Lewis Glyn
Department of Psychological Medicine, University of Wales College of Medicine, Cardiff CF14 4XN.
BMJ. 2002 Nov 23;325(7374):1199. doi: 10.1136/bmj.325.7374.1199.
An association between use of cannabis in adolescence and subsequent risk of schizophrenia was previously reported in a follow up of Swedish conscripts. Arguments were raised that this association may be due to use of drugs other than cannabis and that personality traits may have confounded results. We performed a further analysis of this cohort to address these uncertainties while extending the follow up period to identify additional cases.
Historical cohort study.
1969-70 survey of Swedish conscripts (>97% of the country's male population aged 18-20).
50 087 subjects: data were available on self reported use of cannabis and other drugs, and on several social and psychological characteristics.
Admissions to hospital for ICD-8/9 schizophrenia and other psychoses, as determined by record linkage.
Cannabis was associated with an increased risk of developing schizophrenia in a dose dependent fashion both for subjects who had ever used cannabis (adjusted odds ratio for linear trend of increasing frequency 1.2, 95% confidence interval 1.1 to 1.4, P<0.001), and for subjects who had used only cannabis and no other drugs (adjusted odds ratio for linear trend 1.3, 1.1 to 1.5, P<0.015). The adjusted odds ratio for using cannabis >50 times was 6.7 (2.1 to 21.7) in the cannabis only group. Similar results were obtained when analysis was restricted to subjects developing schizophrenia after five years after conscription, to exclude prodromal cases.
Cannabis use is associated with an increased risk of developing schizophrenia, consistent with a causal relation. This association is not explained by use of other psychoactive drugs or personality traits relating to social integration.
先前在一项对瑞典应征入伍者的随访研究中报告了青少年使用大麻与随后患精神分裂症风险之间的关联。有人提出,这种关联可能是由于使用了大麻以外的其他药物,并且人格特质可能混淆了研究结果。我们对该队列进行了进一步分析,以解决这些不确定性,同时延长随访期以识别更多病例。
历史性队列研究。
1969 - 1970年对瑞典应征入伍者(占该国18 - 20岁男性人口的97%以上)进行的调查。
50087名受试者:有关于自我报告的大麻及其他药物使用情况以及若干社会和心理特征的数据。
通过记录链接确定的因国际疾病分类第8/9版精神分裂症和其他精神病而住院的情况。
大麻使用与患精神分裂症风险增加呈剂量依赖性相关,这在曾经使用过大麻的受试者中(使用频率增加的线性趋势的调整比值比为1.2,95%置信区间为1.1至1.4,P<0.001)以及仅使用过大麻且未使用其他药物的受试者中(线性趋势的调整比值比为1.3,1.1至1.5,P<0.015)均如此。在仅使用大麻的组中,使用大麻超过50次的调整比值比为6.7(2.1至21.7)。当分析仅限于征兵后五年后患精神分裂症的受试者以排除前驱病例时,获得了类似结果。
大麻使用与患精神分裂症风险增加相关,符合因果关系。这种关联不能用使用其他精神活性药物或与社会融合相关的人格特质来解释。